# CJC-1295 Ipamorelin Dosage in the Research Literature (Not a Protocol) > CJC-1295 Ipamorelin dosage as it appears in the research record: the µg/kg ranges studied in humans and rodents, by route and species — with the half-life split, and no human protocol. What was administered, to which species, by which route, at what amount. No human regimen, because none has been validated. ## The gist There is no validated human dose for CJC-1295 Ipamorelin, and this page does not provide one. What exists is a scattered set of research doses, each tied to a species and a route. CJC-1295 with DAC was studied in healthy adults at 30 to 90 micrograms per kilogram of body weight, given under the skin [1]. Ipamorelin's numbers come almost entirely from animals — for example, around 1 microgram per kilogram plateaued the growth-hormone response in rodent models. The two halves also behave on totally different clocks: the DAC version of CJC-1295 lasts days, the no-DAC version about half an hour, and ipamorelin a couple of hours. Everything below is reported as "studied at X in [species] by [route]." None of it is an instruction, and the combination itself has never had its dosing characterized in a human trial. ## Cjc 1295 ipamorelin dosage: what the research recorded Reading the literature as a record rather than a recipe, the CJC-1295 Ipamorelin dosage picture is as follows. **CJC-1295 with DAC.** Studied in human Phase 1 pharmacokinetic work at 30 to 90 µg/kg subcutaneously [1]. In GHRH-knockout mouse studies, roughly 2 µg/day was used. **CJC-1295 no-DAC (the short form).** No formal standalone human pharmacokinetic study exists; research protocols modelled it at roughly 100 to 200 µg per injection as a short, pulsatile releasing signal. **Ipamorelin.** Rodent dosing spanned 100 µg/kg three times daily in bone studies, 0.5 mg/kg/day for bone-mineral endpoints, and 0.01 to 1 mg/kg intravenously for gastrointestinal-motility work; about 1 µg/kg plateaued the growth-hormone response in rodent models. No validated human pharmacokinetic dose is published. Note what is missing: there is no peer-reviewed human pharmacology study of the pre-mixed combination, so there is no studied combination dose to report at all [1][2]. ## Half-life and the with-DAC vs no-DAC clock The single most important dosing fact about this pair is that "CJC-1295" has two half-lives. CJC-1295 with DAC runs about six to eight days in humans — the albumin-bound peptide is still detectable in rat plasma beyond 72 hours [1][5]. CJC-1295 without DAC, Mod GRF (1-29), runs on the order of minutes to about 30 minutes, like native releasing hormone, because DPP-IV cleaves it rapidly. Ipamorelin clears in under about two hours in rodent plasma, with peak growth-hormone response near 40 minutes post-dose; no validated human half-life is published [2]. The practical consequence sits in the safety logic, not in a protocol: pairing the days-long DAC version with a hours-long ipamorelin pulse is a different exposure than pairing the 30-minute no-DAC version with it, and the synergy literature studied short pulses [3]. ## Mod grf 1-29: the no-DAC distinction Mod GRF (1-29) is simply CJC-1295 without the Drug Affinity Complex — the same 29-amino-acid modified releasing-hormone fragment, minus the albumin-binding handle. The result is a short, pulsatile action with no multi-day tail. This is the version used when a protocol is designed around mimicking a natural growth-hormone burst rather than holding the axis elevated for days. It is also why source labelling matters so much in this space: "CJC-1295" with no qualifier is ambiguous, and the no-DAC and with-DAC forms produce entirely different growth-hormone exposure curves [5]. ## Routes, handling, and the human-data gap Routes studied across the two peptides include subcutaneous and intravenous administration, continuous subcutaneous infusion via osmotic minipump in rodent models, and intranasal delivery in rodent ipamorelin pharmacokinetic work. As a handling matter, lyophilised (freeze-dried) peptide is stable frozen for extended periods; once reconstituted with bacteriostatic water, aqueous peptide is kept refrigerated and degrades over weeks via asparagine deamidation, with degradation products markedly less potent. This is standard laboratory-handling context only. On the clinical record: CJC-1295 with DAC reached Phase 2 with ConjuChem before development was discontinued, with public reporting attributing the end of one Phase 2 program to an adverse event in a single subject unrelated to the established mechanism [1]. Ipamorelin was investigated, including for postoperative ileus, but was never advanced to approval. Combination dosing has no human characterization at all. --- A cool-pressed editorial reading of the CJC-1295 and ipamorelin literature, set in ruled columns — the mechanism, the with-DAC and no-DAC clocks, and the combination trial that was never run, each line cited; no clinic behind the masthead and nothing here dosed, prescribed, or sold.